Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy

INTRODUCTION: Ziprasidone (ZP) is a novel atypical antipsychotic agent effective in the treatment of positive and negative symptoms of schizophrenia with low chances for extrapyramidal side effects (EPs) and cognitive deficits. ZP possesses poor oral bioavailability (~50%), short biological half-lif...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Urooj A, Parveen, Uzma, Hasan, Nazeer, Ahmed, Mohammad Zubair, Saad, Suma, Ahmad, Farhan J, Jain, Gaurav K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294276/
https://www.ncbi.nlm.nih.gov/pubmed/32606594
http://dx.doi.org/10.2147/DDDT.S247196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294276/
https://www.ncbi.nlm.nih.gov/pubmed/32606594
http://dx.doi.org/10.2147/DDDT.S247196

Ejemplares similares